The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
IL-10 and its related cytokines for treatment of inflammatory bowel disease
Open accessAbstract
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are chronic inflammatory disorders of gastrointestinal tract. Although the etiology is incompletely understood, initiation and aggravation of the inflammatory process seem to be due to a massive local mucosal immune response. Interleukin-10 (IL-10) is a regulatory cytokine which inhibits both antigen presentation and subsequent pro-inflammatory cytokine release, and it is proposed as a potent anti-inflammatory biological therapy in chronic IBD. Many methods of IL-10 as a treatment for IBD have been published. The new strategies of IL-10 treatment, including recombinant IL-10, the use of genetically modified bacteria, gelatine microsphere containing IL-10, adenoviral vectors encoding IL-10 and combining regulatory T cells are discussed in this review. The advantages and disadvantages of these IL-10 therapies are summarized. Although most results of recombinant IL-10 therapies are disappointing in clinical testing because of lacking efficacy or side effects, therapeutic strategies utilizing gene therapy may enhance mucosal delivery and increase therapeutic response. Novel IL-10-related cytokines, including IL-19, IL-20, IL-22, IL-24, IL-26, IL-28 and IL-29, are involved in regulation of inflammatory and immune responses. The use of IL-10 and IL-10-related cytokines will provide new insights into cell-based and gene-based treatment against IBD in near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lindsay, J. O., Ciesielski, C. J., Scheinin, T., Brennan, F. M., & Hodgson, H. J. F. (2003) · Gut · doi:10.1136/gut.52.3.363 · Cited by 73
RetractedIFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10
Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., & Remaut, E. (2000) · Science · doi:10.1126/science.289.5483.1352 · Cited by 1,513
The Immunology of Mucosal Models of Inflammation
Strober, W., Fuss, I. J., & Blumberg, R. S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064816 · Cited by 1,304
Interleukin-10 Therapy—Review of a New Approach
Asadullah, K., Sterry, W., & Volk, H. D. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.2.4 · Cited by 946
Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S., & Levings, M. K. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820105.x · Cited by 814
Blumberg, H., Conklin, D., Xu, W., Grossmann, A., Brender, T., Carollo, S., Eagan, M., Foster, D., Haldeman, B. A., Hammond, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00187-8 · Cited by 547
Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, E., Remon, J. P., & Remaut, E. (2003) · Nature Biotechnology · doi:10.1038/nbt840 · Cited by 542
Fedorak, R. N., Gangl, A., Elson, C. O., Rutgeerts, P., Schreiber, S., Wild, G., Hanauer, S. B., Kilian, A., Cohard, M., LeBeaut, A., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.20229 · Cited by 512
Cited by
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J.-M., Diepolder, H., Marquardt, A., Jagla, W., Popp, A., et al. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00513.2005 · Cited by 549
The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis
Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., & Keswani, S. G. (2020) · Advances in Wound Care · doi:10.1089/wound.2019.1032 · Cited by 433
Diversity in the contribution of interleukin‐10 to T‐cell‐mediated immune regulation
Maynard, C. L., & Weaver, C. T. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00711.x · Cited by 402
Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease
Mirsepasi-Lauridsen, H. C., Vallance, B. A., Krogfelt, K. A., & Petersen, A. M. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-18 · Cited by 359
Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Veiga, N., Goldsmith, M., Granot, Y., Rosenblum, D., Dammes, N., Kedmi, R., Ramishetti, S., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06936-1 · Cited by 308
Fibrosis Related Inflammatory Mediators: Role of the IL‐10 Cytokine Family
Sziksz, E., Pap, D., Lippai, R., Béres, N. J., Fekete, A., Szabó, A. J., & Vannay, Á. (2015) · Mediators of Inflammation · doi:10.1155/2015/764641 · Cited by 265
Immune dysfunction in inflammatory bowel disease
Neuman, M. G. (2007) · Translational Research · doi:10.1016/j.trsl.2006.11.009 · Cited by 255
Carrillo‐Vico, A., Lardone, P. J., Naji, L., Fernández‐Santos, J. M., Martín‐Lacave, I., Guerrero, J. M., & Calvo, J. R. (2005) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2005.00265.x · Cited by 204
Metadata
- Authors
- Li, M.-C.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2004
- Volume
- 10
- Issue
- 5
- Pages
- 620
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W72719101
- Cited by
- 277
- References
- 46
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.